MediciNova, Inc. (NASDAQ: MNOV, TSE: 4875) is a late-stage, global biopharmaceutical company that is developing novel therapeutics with a primary focus on neurodegenerative disorders, beginning with Amyotrophic Lateral Sclerosis (ALS), with a secondary focus on conditions like respiratory and liver disease, fibrotic diseases, acute lung injury, metabolic diseases, and more with high unmet need. MediciNova’s goal is to address the unmet needs many patients are dealing with in these spaces, providing solutions and treatments to further address them while improving quality of life.
Company Details
- Employees
- 15
- Address
- 4275 Executive Square,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://medicinova.com/
- HQ
- La Jolla, CA
Medicinova, Inc. Questions
Medicinova, Inc.'s website is https://medicinova.com/
Medicinova, Inc.'s LinkedIn profile is https://www.linkedin.com/company/medicinova-inc.
Medicinova, Inc. has
15 employees.
View email and phone details for 15
employees at Medicinova, Inc..
Medicinova, Inc.'s industry is
Biotechnology Research
Medicinova, Inc.'s top competitors are
Biocom California,
Cenna Biosciences,
Cardiff Advisory Llc,
Briacell Therapeutics Corp.,
Omega Bio-Tek,
Geovax Labs, Inc.,
Minovia Therapeutics,
Ilc Therapeutics,
Candid Therapeutics,
Inmed Pharmaceuticals.
Medicinova, Inc.'s categories are Biotechnology Research
